Our Mission in Needle Free Drug Delivery in 2012

In over 25 years, the painless, needle free delivery of drugs has intrigued people around the world as well as the  investment community. In the past, numerous companies have failed and investments were lost forever. None of these companies were able to prove that their needle free injector worked. For several years, investors have read about collaboration with partners from the pharmaceutical industry. Unfortunately, many of these alliances never materialized into product, which was intended to be marketed and sold to end users.

I had a prototype of INJEX in my possession, for the very first time in November 1998. By the year 2000, Rösch AG had an IPO at the Frankfurt Stock Exchange. INJEX had CE approval, and a fully automated production line. Several studies were performed and we developed sterile disposables that were ready for production. However, we experienced a setback. This was especially true in the European diabetes market, which was controlled by pharmaceutical companies.

Companies like GlidePharma, UK or Crossject, Paris, still collect money for ongoing research and development. While other companies like Antares Pharma sustained losses in 2011, they nonetheless are still a highlight for their shareholders and their market cap is currently $330 million US.

Today, our aim is to show that people worldwide will use the needle free injection system. Our success in the marketplace will motivate the pharmaceutical industry to show interest in our R&D project for prefilled ampoules. These will be used with both INJEX and the single use ROJEX.

In 2012, many new markets have opened up. In the beauty market, the demand for wrinkle treatments is growing rapidly. Hyaluronic acid is being administered using INJEX. Many test markets have demonstrated positive results.

Today we are well prepared for this emerging market. We are in the process of launching our new beauty line Shireen. This will include injections using hyaluronic acid, vitamin B to refresh the skin and vitamin C to treat dark spots.

Ten years ago in dentistry, INJEX was used for local anaesthetic on the front teeth only. Today dentists in Australia have discovered that it can be used on ALL teeth for almost all dental treatments.

INJEX30, the virtually painless needle free injection is finally a global commodity. People can now buy it and benefit from this new technology. Physicians are asking for INJEX so that they can provide innovative treatments for their patients, as well as alleviating the stress and anxiety associated with traditional needles.

We have developed a very strong, professional marketing and sales team. We recognize the importance of continuing our R & D. In conclusion, we are different; we are dynamic and look forward to providing this innovative device for all.